Acta Med. 2012, 55: 142-145
https://doi.org/10.14712/18059694.2015.53
CASE 2–2012: a 57-Year-Old Woman with Post-Transplant Lymphoproliferative Disorder after Allogeneic Stem Cell Transplantation for Primary Myelofibrosis
References
1. B, Morel P, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996; 88(3): 1013–83.
<https://doi.org/10.1182/blood.V88.3.1013.1013>
2. SM, Juvonen E, et al. Lymphoproliferative disease after allogeneic stem cell transplantation – pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. Journal of Clinical Virology: the official publication of the Pan American Society for Clinical Virology. 2003; 28(3): 275–83.
<https://doi.org/10.1016/S1386-6532(03)00022-2>
3. F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients. Virology Journal. 2011; 8: 421.
<https://doi.org/10.1186/1743-422X-8-421>
<PubMed>
4. DM, Ambrossi GG , Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplantation. 2006; 37(6): 539–46.
<https://doi.org/10.1038/sj.bmt.1705289>
5. J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein- Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transplant Infectious Disease: an official journal of the Transplantation Society. 2009; 11(5): 383–92.
<https://doi.org/10.1111/j.1399-3062.2009.00411.x>
6. BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein- Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? The American Journal of Surgical Pathology. 2000; 24(3): 375–85.
<https://doi.org/10.1097/00000478-200003000-00006>
7. G, Hajdu M, Sebestyen A. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options. Pathology Oncology Research: POR. 2011; 17(3): 443–54.
<https://doi.org/10.1007/s12253-010-9329-8>
8. A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. American Journal of Transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2006; 6(2): 262–74.
<https://doi.org/10.1111/j.1600-6143.2005.01207.x>
9. JW, Niesters HG, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002; 99(12): 4364–9.
<https://doi.org/10.1182/blood.V99.12.4364>
10. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th Edition. Ed. by Swerdlow SH, Campo E, Harris NL, et al., IARC, Lyon, 2008, 343–349.
